IVVD Q4 2025 Earnings — Invivyd, Inc. Revenue & Financial Results | Market Cap Arena

IVVDInvivyd, Inc.

$257M

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$17M+24.5% YoY

Gross Profit

$16M93.4% margin

Operating Income

-$13M-73.0% margin

Net Income

-$11M-64.3% margin

EPS (Diluted)

$-0.06

QoQ Revenue Growth

+31.1%

Cash Flow

Operating Cash Flow

-$15M

Free Cash Flow

-$15M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$277M

Total Liabilities

$35M

Stockholders' Equity

$242M

Cash & Equivalents

$227M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$17M	$14M	+24.5%
Gross Profit	$16M	$13M	+22.7%
Operating Income	-$13M	-$19M	+34.7%
Net Income	-$11M	-$18M	+40.0%

Revenue Segments

Product

$17M100%